2022 News Releases
Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference
LOS ANGELES, Calif., March 7, 2022 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a
biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer,
President and Founder of Puma, will participate in a panel discussion on breast cancer at Cowen’s 42 nd
Annual Health Care Conference, which will be held virtually. The Breast Cancer Panel will take place
on Wednesday, March 9, at 2:10 p.m. ET.
A live webcast of the presentation will be available on the Company’s website at
https://www.pumabiotechnology.com. The presentation will be archived on the website and available for
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and
commercialization of innovative products to enhance cancer care. The Company in-licenses the global
development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and
PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the
extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast
cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in
combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-
positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic
setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the
extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-positive
overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant
trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
# # # # #
Back to 2022 News Releases
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024